Research

*July 2023* Targeted therapies and the complex landscape after progression on osimertinib/Tagrisso. You can now watch it on demand here. It's extremely informative! View the presentation slides here.

*July 2023* With osimertinib (Tagrisso) available as a treatment option in both the metastatic and adjuvant settings for patients with EGFR-mutated non–small cell lung cpatients with EGFR-mutated non–small cell lung cancer ancer (NSCLC) and ongoing trials evaluating combination therapies for this patient population, molecular testing to identify these aberrations in patients with…

*July 2023* The Lung-MAP Accrual Enhancement Committee (AEC) hosted this webinar which featured leading experts from the current Lung-MAP clinical trial to discuss recent trial updates, challenges to the traditional clinical trial landscape that Lung-MAP is working to overcome, and opportunities for patient engagement in the process. Importantly, the webinar featured a panel…

*June 2023* In Hollywood, the word "mutant" generally has a negative connotation, with movie plot lines that involve rogue mutants, mercenary mutants, or hunted mutants. But in the lung cancer space, harboring an EGFR mutation may confer an advantage. In a study that sought to pinpoint survival outcomes for patients with synchronous oligometastatic…

*June 2023* Key Points: KEYNOTE-789 did not show a significant improvement in PFS or OS with the addition of pembrolizumab to chemotherapy in patients with TKI-resistant EGFR-mutated metastatic nonsquamous NSCLC. There remains a need for more effective treatment strategies for patients with EGFR-mutated NSCLC. An analysis from the randomized, phase 3 KEYNOTE-789…

*June 2023* EGFR Resisters and LCRF are delighted to update supporters about the research made possible by their partnership! The EGFR Resisters Grant was awarded in 2021 to Yang Tian, PhD, Icahn School of Medicine at Mount Sinai. She joins us along with Hideo Watanabe, MD, PhD, who leads The Watanabe…

*May 2023* Long-term data from the CHRYSALIS trial (NCT02609776) continued to demonstrate clinical benefit for amivantamabvmjw (Rybrevant), according to findings presented at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.1 At a median follow-up of 19.2 months, median progression-free survival (PFS) with the agent was 6.9 months (95% CI,…

*May 2023* Nearly half of all brain tumors are associated with an underlying cancer diagnosis, and lung cancer is one of the most common of these. As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.…

*May 2023* The emergence of immune checkpoint inhibitors has dramatically altered the treatment landscape of stage IV NSCLC with some patients now experiencing unprecedented long-term survival after PD-1/PD-L1 therapy. These individuals that benefit typically have smoking-induced lung tumors, while patients who have never smoked or have EGFR-driven NSCLC, generally possess…

*May 2023* Positive findings from the FLAURA2 study add to the body of evidence supporting treatment with osimertinib for patients with EGFRm non–small cell lung cancer.mpared to osimertinib alone and as such, can further delay treatment resistance and disease progression.” The combination of osimertinib (Tagrisso) with chemotherapy generated a statistically significant…